{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001895","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.566261+00:00","generated_at":"2026-05-24T01:57:01.879389+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivos Therapeutics reports FY2024 revenue up 9% to $15M; operating loss narrows 35%","bullets":["Revenue $15.0M (+9% YoY); product revenue increased 26%; gross profit $9.0M at 60% margin.","Operating loss reduced 35% to $11.2M from $17.3M; operating expenses down 21%.","Cash $6.3M; raised $17.9M via four equity transactions including $7.5M from New Seneca Partners.","FDA 510(k) clearance for DNA appliance to treat moderate-to-severe OSA in children ages 6-17.","New strategic alliance with Rebis Health; expects 4-6x increase in revenue per case under new distribution model."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001895","json":"https://secwatch.observer/filing/0001641172-25-001895.json","markdown":"https://secwatch.observer/filing/0001641172-25-001895.md","text":"https://secwatch.observer/filing/0001641172-25-001895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000164117225001895/0001641172-25-001895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000164117225001895/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:57:01.879389+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}